Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA 24 FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of dysmenorrhea (off-label),Acne vulgaris (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily metabolized via CYP3A4. Norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes phase I (hydroxylation via CYP3A4) and phase II (glucuronidation) metabolism.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~91% to albumin and SHBG; Ethinyl estradiol: ~97% to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: ~1.5 L/kg; Ethinyl estradiol: ~15 L/kg. Indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: ~64%; Ethinyl estradiol: ~43% (oral).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or acute renal failure due to potential accumulation of components.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment or active liver disease. No specific dose adjustments provided for mild impairment; use not recommended in Child-Pugh class B or C.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy established in females of reproductive age post-menarche. Dosing same as adults (0.10 mg/1.0 mg daily for 24 days, then placebo for 4 days).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dose adjustments required for elderly, but consider risks of thromboembolism and other comorbidities.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Hepatic neoplasia,Gallbladder disease,Hypertension,Hyperkalemia in renal impairment (due to drospirenone component in some formulations; not applicable to this product),Glucose intolerance,Depression,Uterine bleeding irregularities,Follicular atresia and amenorrhea after discontinuation,Contact lens intolerance
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal vaginal bleeding,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Hepatic adenoma or carcinoma,Active liver disease with impaired function,Hypersensitivity to any component,Smoking in women over 35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No food interactions documented. Grapefruit juice may increase estrogen exposure but not clinically significant; no restriction needed.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and potential for neonatal hepatic dysfunction. Contraindicated in pregnancy due to teratogenicity.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in low amounts; M/P ratio not well established. Use during lactation is generally not recommended due to potential adverse effects on infant, including jaundice and hormonal changes. May suppress milk production.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; use is contraindicated during pregnancy. No dose adjustment can mitigate fetal risk; immediate discontinuation upon confirmed pregnancy is required.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
AUROVELA 24 FE is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate placebo. The iron supplement in placebo pills is not bioavailable and does not treat iron deficiency. Counsel that withdrawal bleed typically occurs during the 4th week (iron pills). Missed pills algorithm: if one active pill missed, take as soon as remembered; if two or more missed, take last missed and use backup contraception for 7 days. Induction of CYP3A4 by rifampin, anticonvulsants, St. John's wort may reduce efficacy. Do not prescribe with concomitant hepatitis C therapy containing ombitasvir/paritaprevir/ritonavir due to ALT elevations.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, preferably after the evening meal to reduce nausea.,The last 7 tablets are brown iron pills; you will have a withdrawal bleed during this time.,If you vomit within 4 hours of taking an active pill, take another active pill from a separate pack.,Missing two or more active pills may require backup contraception (condoms) for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking while on this medication.,Report any symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA 24 FE vs AFIRMELLE, answered by our medical review team.
AUROVELA 24 FE is a Oral Contraceptive that works by Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA 24 FE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA 24 FE is: One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA 24 FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA 24 FE is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and poten. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.